Polyarteritis Nodosa

What It Is, Causes, Signs and Symptoms, Treatment, and More

Author: Emily Miao, MD, PharmD
Editor: Alyssa Haag, MD
Editor: Józia McGowan, DO
Editor: Kelsey LaFayette, DNP, ARNP, FNP-C
Illustrator: Abbey Richard, MSc
Modified: Jan 06, 2025

What is polyarteritis nodosa?

Polyarteritis nodosa (PAN) is a rare form of systemic vasculitis that results in systemic necrotizing inflammation of the blood vessels. Vasculitides are a heterogeneous group of autoimmune diseases of the blood vessels and occur due to molecular mimicry, an autoimmune response in which the body’s immune system misidentifies normal antigens on the endothelial cells with the antigens of foreign invaders. Vasculitides can be grouped by vessel size (i.e., small, medium, large). PAN is a disease that primarily affects medium-sized blood vessels and multiple organ systems. It results in widespread systemic inflammation and long-term damage to the peripheral nerves.     

PAN is most commonly seen in middle-aged or older adults, with a peak incidence in the sixth decade of life, although children can also be affected. It is slightly more common in those assigned male at birth and is associated with hepatitis B infection. Arterial networks are widely distributed throughout the body, therefore, all organs may potentially be involved. Nonetheless, PAN classically affects the kidneys, gastrointestinal tract, central nervous system, and skin, while sparing the pulmonary system.     

An infographic detailing the background, causes, signs and symptoms, diagnosis, and treatment of polyarteritis nodosa.

What causes polyarteritis nodosa?

PAN is thought to be an autoimmune response to the endothelium (i.e., the innermost layer) of blood vessels, however, the underlying trigger is currently unknown. This autoimmune response, also known as molecular mimicry, occurs when the body’s immune cells directly attack the endothelium confusing it with the antigens seen in the hepatitis B virus. The body normally produces a chronic immune response to hepatitis B infection which results in excess immune-complex deposition along blood vessels and subsequently, chronic inflammation. In PAN, however, the body improperly orchestrates an excessive immune response. While the endothelium is initially affected, the body eventually initiates a widespread inflammatory response, which results in transmural (i.e., entire wall) inflammation of the artery wall including the tunica intima, media, and adventitia. Fibrosis occurs as the vascular wall heals. Vessels with fibrosis are often weak and prone to aneurysms (i.e., abnormal swelling or bulge in the wall of the blood vessel or artery), resulting in a “string of beads” appearance on the angiogram. Rarely, PAN may also be associated with co-infection with the hepatitis C virus 

What are the signs and symptoms of polyarteritis nodosa?

Signs and symptoms of PAN vary based on the distribution of affected arteries, however, the main complication is organ ischemia or inadequate blood supply. If the renal arteries are affected, some patients with PAN may have high blood pressure since the kidneys regulate blood volume and pressure. If the mesenteric artery is affected, individuals may experience abdominal pain, gastrointestinal bleeding, and gastrointestinal symptoms like nausea, anorexia, and weight loss. If the arteries that supply the brain are involved, neurologic symptoms may be apparent including altered mental status, headache, slurred speech, and muscle weakness. Finally, dermatologic involvement may manifest as ulcers and tender erythematous nodules on the skin. 

How is polyarteritis nodosa diagnosed?

Diagnosis of PAN begins with a thorough review of symptoms and medical history. A focused physical examination can help determine the extent of vascular lesions and determine if there is neurologic involvement. A positive fecal occult blood test may be indicative of gastrointestinal involvement. While there are no diagnostic blood tests for PAN, a basic laboratory panel may help characterize the extent of organ involvement. For example, serum creatinine and urinalysis can be useful in the assessment of renal function. Hepatitis B and C serologies should be obtained since chronic hepatitis infection is a risk factor for PAN. Due to the rarity of the disease and severe treatment-related adverse effects, confirmation with a biopsy of an arterial lesion is recommended whenever possible. In the absence of an available biopsy site, imaging with an angiogram or arteriogram (i.e., an imaging procedure that involves injection of a dye into the arteries to help visualize blood flow to organs) may reveal the classic “string of beads” appearance of blood vessels in the renal, hepatic, or mesenteric vasculature.  
 
Moreover, the American College of Rheumatology (ACR) has established ten criteria for the classification of PAN in an individual diagnosed with vasculitis. There is a high likelihood that an individual meets the criteria for PAN if they meet at least three of the following: 

(a) Unexplained weight loss greater than four kilograms 
(b) Presence of livedo reticularis  
(c) Testicular pain and/or tenderness 
(d) Muscle pain excluding the shoulder and hips, muscle weakness, tenderness of leg muscles 

(e) Presence of mononeuropathy or polyneuropathy 
(f) New onset diastolic blood pressure greater than 90 mmHg 
(g) Elevated BUN (>40 mg/dl) or SCr (>1.5 mg/dl) 
(h) Serologic evidence of hepatitis B virus infection 
(i) Presence of “string of beads” appearance on angiography 
(j) Confirmation via biopsy of blood vessel demonstrating polymorphonuclear cells 

Differential diagnoses that can present similarly (i.e., systemic sclerosis, systemic lupus erythematosus, drug-induced vasculitis) should be excluded via a thorough rheumatologic work-up and laboratory testing (e.g., antinuclear antibodies, anti-dsDNA, anti-RNP, scleroderma antibodies).  

How is polyarteritis nodosa treated?

Management of PAN depends on the severity, extent, and etiology of the disease. Individuals with PAN and hepatitis B or C infection should be initiated on antiviral therapy (e.g., tenofovir, entecavir) to treat the underlying hepatitis. In non-severe PAN with no internal organ involvement (i.e., isolated cutaneous involvement), treatment consists of glucocorticoids (e.g., prednisone) for 3 to 4 months, followed by a slow taper to prevent disease relapse and glucocorticoid-related complications (e.g., adrenal insufficiency). In individuals who experience disease relapse or are intolerant of glucocorticoids, immunosuppressive agents (e.g., azathioprine, methotrexate) can be added for maintenance therapy for at least one year. In severe PAN (i.e., life-threatening or has internal organ involvement) a chemotherapy agent, cyclophosphamide, is added in addition to glucocorticoids for remission induction. Plasma exchange can be considered in individuals with severe disease where immunosuppressive therapy is contraindicated. After plasma exchange, individuals are typically initiated on maintenance cyclophosphamide and immunosuppressive therapy (e.g. azathioprine, methotrexate) for at least one year. 

What are the most important facts to know about polyarteritis nodosa?

Polyarteritis nodosa (PAN) is a rare form of systemic vasculitis that results in systemic necrotizing inflammation of the blood vessels. PAN primarily affects medium-sized muscular arteries. PAN is thought to occur when the body’s immune cells directly attack the endothelium, confusing it with the antigens seen in hepatitis B virus or chronic hepatitis infection.  However, the primary trigger for this autoimmune response is unclear. Patients with PAN may experience a variety of symptoms depending on the distribution of affected arteries. Diagnosis of PAN via biopsy of an affected artery is recommended whenever possible. The American College of Rheumatology (ACR) has established ten criteria in an individual diagnosed with vasculitis to help identify individuals with PAN. Management includes corticosteroids, cyclophosphamide, and immunosuppressive maintenance therapy. 

References


Chung SA, Gorelik M, Langford CA, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa. Arthritis Care Res (Hoboken). 2021;73(8):1061-1070. doi:10.1002/acr.24633  


De Virgilio A, Greco A, Magliulo G, et al. Polyarteritis nodosa: A contemporary overview. Autoimmun Rev. 2016;15(6):564-570. doi:10.1016/j.autrev.2016.02.015 


Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967;43(1):8-14. doi:10.1016/0002-9343(67)90144-1 


Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial. 2003;7(2):155-160. doi:10.1046/j.1526-0968.2003.00036.x 


Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715 


Moore PM. Neurological manifestation of vasculitis: update on immunopathogenic mechanisms and clinical features. Ann Neurol. 1995;37 Suppl 1:S131-S141. doi:10.1002/ana.410370713